Delaware-based Ignyta (RXDX) is focused on precision medicine in oncology. It endeavors to eradicate residual disease or the source of a reoccurrence of cancer in targeted patient populations.
Ignyta is pursuing an integrated therapeutic and diagnostic strategy to treat cancer patients. Its therapeutic efforts are focused on in-licensing or acquiring and then developing and commercializing targeted therapies that can be used to remove residual disease. Its diagnostic efforts aim to combine these therapeutic drug candidates with biomarker-based diagnostics that can identify patients who can benefit from the precision therapies it’s developing.
Of the four analysts covering Ignyta in January 2018, all of them have given the stock a “hold” rating. The mean rating for the stock is 3.0 with a target price of $28.
Ignyta makes up 1.2% of the total portfolio holdings of the SPDR S&P Biotech ETF (XBI).
Of the 24 analysts covering Pfizer (PFE) in January 2018, 13 of them have given the stock a “buy” or higher rating. Nine analysts have given the stock a “hold” rating, and the remaining two have given it a “sell” rating. The mean rating for the stock is 2.54 with a target price of $38.29.
Of the 30 analysts covering Novartis (NVS) in January 2018, 14 of them have given the stock a “buy” or higher rating. The mean rating for the stock is 2.47 with a target price of $86.73.
Of the eight analysts covering Loxo Oncology (LOXO) in January 2018, five of them have given the stock a “strong buy” rating, and three have given it a “buy.” The mean rating for the stock is 1.38 with a target price of $110.83.
In the next part of this series, we’ll take a look at Ignyta’s licensing agreements.